On Monday, Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY), gained 14.32% to $0.87.
Yesterday, Oncolytics Biotech, declared that a series of poster presentations by the Company’s research collaborators will be made at the 2015 AACR Annual Meeting being held from April 18th to 22nd, 2015 in Philadelphia, PA.
The first abstract/poster titled “Combination therapy of reovirus and PD-1 blockade effectively established tumor control via innate and adaptive immune responses,” was authored by Melcher, et al. The authors concluded that in an immune-competent murine melanoma model the combination therapy of reovirus with PD-1 blockade confers noteworthysurvival benefit, by augmenting tumor-specific natural killer (NK) responses and specifically attenuating tumor-specific immunosuppression. These data also suggest that combination of PD-1 inhibition therapy with reovirus oncolytic/immunotherapy represents a readily translatable method to enhance the therapeutic efficacy.
The second abstract/poster titled “Oncolytic virus (RT3D) administration in combination with cetuximab in head and neck squamous cell cancer (HNSCC) models harboring active EGFR/RAS/P13K signaling,” was authored by Psyrri, et al. The authors concluded that in a transgenic mouse to test the therapeutic effect of combination of cetuximab treatment and RT3D infection in a mouse model of ras-driven oral SCC, RT3D infection exhibits a strong oncolytic effect in cetuximab resistant HNSCC with activated EGFR/RAS/MAPK signaling. The findings offered evidence that RAS independent molecular mechanisms can also support the RT3D proliferation in this subset of HNSCC.
The third abstract/poster titled “Synergistic mechanisms of oncolytic reovirus with bortezomib in overcoming therapy resistance of multiple myeloma,” was authored by Morris et al. Using a number of multiple myeloma cell lines the authors concluded that not all multiple myeloma cell lines are amenable to reovrius mediated cell death and that this has important implications for the future use of reovirus as a therapeutic agent. Understanding the signaling pathways of resistant tumours will assist develop a more personalized approach for reovrius therapy for multiple myeloma patients in the future.
The fourth abstract/poster titled “Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer (NSCLC),” was also authored by Morris et al. Using reovirus and sunitinib the researchers tested series of human and mouse lung cancer cell lines and concluded that reovirus and sunitinib combination therapy holds promise as a novel treatment strategy for NSCLC.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.
Shares of Hasbro Inc. (NASDAQ:HAS), gained 12.55% to $74.16, during its last trading session, hitting its highest level.
Yesterday, Hasbro declared that it has been named as the second most transparent and responsible company in the U.S., according to the 100 Best Corporate Citizens List for 2015. This is the second time that Hasbro has ranked in the Top 10 and the fourth successive year that the Company has ranked in the Top 25.
The Company ranked #2 this year, rising 20 spots, in recognition of its stellar performance in seven key areas: environment, climate change, employee relations, human rights, governance, finance, and philanthropy.
The 100 Best Corporate Citizens List documents 303 data points of disclosure and performance measures —from publicly accessible information in seven categories: environment, climate change, employee relations, human rights, governance, finance, and philanthropy & community support.
Hasbro, Inc., together with its auxiliaries, provides children’s and family leisure time products and services worldwide. The company’s product offerings comprise various toys comprising boys action figures, vehicles and playsets, girls toys, electronic toys and games, plush products, preschool toys and infant products, electronic interactive products, creative play, and toy-related specialty products.
At the end of Monday’s trade, Shares of Rovi Corporation (NASDAQ:ROVI), gained 8.64% to $19.11.
Yesterday, Rovi Corporation declared that Rovi has renewed its patent license and interactive program guide (IPG) product contract with Charter Communications, Inc. The license renewal extends Charter’s IPG patent license. Under the terms of the contract, Charter will also be able to license Rovi’s products and services, counting Rovi Search, Recommendations and Conversation Services, Rovi Metadata and Rovi Analytics.
Rovi Search and Recommendations Services are built upon a predictive process that analyzes past viewing behaviors and preferences. Rovi uniquely combines entertainment metadata with a dynamic Knowledge Graph that maintains semantic, real-time information on more than 100 million entertainment-related entities. Rovi Conversation Services create intuitive ways for consumers to discover and access huge libraries of programming, bringing a next-generation user experience to television and video applications with naturally spoken language. Rovi Analytics provides data-driven insights and business intelligence to advance operational efficiency, improve customer experience and support business decisions to assist mitigate churn.
Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The company offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording.
Finally, TASER International Inc. (NASDAQ:TASR), ended its last trade with 6.94% gain, and closed at $30.37, hitting its highest level.
TASER International declared multiple orders of its TASER® brand next generation Smart Weapons. These orders were received in the first quarter and are predictable to be shipped in the first half of 2015.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
